All In Biotech

Drug Trial Radar · NCT06642272

A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record

Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 17,200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

17,200

Planned (sponsor's estimate)

Start

Oct 10, 2024

Primary completion

Dec 31, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Herlev and Gentofte HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this clinical trial is investigate the comparative effectiveness of empagliflozin and dapagliflozin for the treatment of diabetes, chronic kidney disease, and heart failure. Patients who are prescribed either empagliflozin or dapagliflozin, as part of daily clinical practice at the participating sites, will be included in the study. Treatment will be randomized automatically through the electronic health record software in clusters defined by time of day. https://www.appletreestudy.com

Conditions

  • Diabetes Mellitus, Type 2
  • Heart Failure
  • Chronic Kidney Diseases

Interventions

  • Empagliflozin 10 MGDrug

    Once daily

  • Dapagliflozin 10 MGDrug

    Once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to the first occurrence of any of the components of the composite: all-cause mortality, hospitalization for heart failure, hospitalization for myocardial infarction, hospitalization for ischemic stroke, and incident or worsening nephropathy.Time frame: Up to 24 months

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Bispebjerg Hospital

    Copenhagen, Denmark · Recruiting

  • Rigshospitalet

    Copenhagen, Denmark · Recruiting

  • Herlev and Gentofte Hospital

    Herlev, Denmark · Recruiting

  • Steno Diabetes Center Copenhagen

    Herlev, Denmark · Recruiting

  • Nordsjællands Hospital

    Hillerød, Denmark · Recruiting

  • Holbæk Sygehus

    Holbæk, Denmark · Recruiting

  • Hvidovre Hospital

    Hvidovre, Denmark · Recruiting

  • Sjællands Universitetshospital

    Køge, Denmark · Recruiting

  • Nykøbing F. Sygehus

    Nykøbing Falster, Denmark · Recruiting

  • Bornholms Hospital

    Rønne, Denmark · Recruiting

  • Sjællands Universitetshospital

    Roskilde, Denmark · Recruiting

  • Slagelse Sygehus

    Slagelse, Denmark · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.